Article History
Received: 15 September 2021
Accepted: 13 December 2021
First Online: 8 January 2022
Declarations
:
: There are no competing interests to declare. The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The data that support the findings of this study are available from corresponding author. Restrictions apply to the availability of these data, which were used under license for this study.
: The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the Italian Medicines Agency or their Committee. LP has consulted for AbbVie USA; Acadia USA; BCG Switzerland; Boehringer Ingelheim International GmbH; Compass Pathways, UK; Ferrer Spain, EDRA-LSWR Publishing Company, Italy; Inpeco SA Lab Automation Company, Switzerland; Johnson & Johnson USA; NeuroCog Trials USA; Otsuka USA, Pfizer Global USA; PharmaMar Spain; Takeda, USA and VeraSci USA.
: SMC carried out the analysis on the Osmed Database data, the bibliographical search, screened studies for inclusion, recorded the motivation for the exclusion of any study considered, performed data extraction and analysis, and drafted the manuscript; GC participated in the discussion related to the selection process in case of discrepancies, checked the forms containing the data extraction, revised the manuscript. NL revised the manuscript. LP and AM provided methodological advice and revised the manuscript. All authors read and approved the final manuscript.
: Given the nature (not clinical) of the study, exclusively based on the administrative anonymous data with no disclosure of confidential/sensitive information, approval by an ethics committees and informed consent were not required, in accordance with the local legislation and institutional requirements.
: Not applicable.
: Not applicable.
: Not applicable.